|
Interferon
Gamma Has No Effect on HCV RNA Levels in Relapsers and Nonresponders
to Interferon Alfa-based Regimens
Currently,
there are no effective therapies available for patients with
chronic hepatitis C who have failed
to respond to optimal interferon
alfa-based regimens. The aims of this pilot
study were to assess the antiviral activity and safety of
interferon
gamma in chronic
hepatitis C.
Patients with chronic hepatitis
C genotype 1 who had not responded to or who
had relapsed
after therapy with interferon alfa and ribavirin
were enrolled in a trial of interferon gamma 1b given in doses
of 100, 200 or 400μg subcutaneously three times weekly
for 4 weeks. Frequent blood samples were obtained for HCV RNA
levels.
Results
· Fourteen patients
were enrolled.
· Geometric mean HCV
RNA levels remained unchanged.
· Serum aminotransferase
levels also did not change, while there were
significant decreases in neutrophil counts (−41% from
baseline) and hematocrit (−5%).
· Low
grade fever and malaise were common with the first injection
of interferon gamma, but no serious side effects were encountered.
The
authors conclude, “Although relatively well-tolerated, interferon
gamma in doses of 100–400μg thrice weekly had no effect
on HCV RNA levels in patients with chronic hepatitis C who
had failed to achieve a sustained response to interferon alfa-based
therapies.”
06/24/05
Reference
A Soza
and others. Pilot study of interferon gamma for chronic hepatitis
C. Journal of Hepatology. Published online April 26,
2005.
All
HCV Topics [
A to Z ]
2-log
Drop
Acute (Primary) HCV
Infection
Age
Alcohol / Smoking
/ Diabetes
ALT
Anemia
Children
Chronic HCV Infection
Cirrhosis
Cognitive Behavioral
Therapy
Complementary Therapies
(CAM)
Combination Treatment
Cryoglobulinemia
/ Cryoglobulin
Disease Progression
Decompensation
Developing Countries
Depression
Diabetes Mellitus
Dosing
Drug Abuse
Drug Pricing
Drug Related Adverse Events
Early Treatment Cessation
Early Virologic Response
Epidemiology / African
Americans
Epoetin Alpha
Early Viral Response
(EVR)
Eradication
Extrahepatic
Events
Experimental Treatment
Experimental
Therapy (procedure)
Fibrosis
Gender
Genetics
Genotype
1 and 4
Genotype
2 and 3
Genotype 5
and 6
GGT Levels
Glucose Intolerance
Growth Factors
Guidelines
HCV
Clearance
HCV Disease
Progression
HCV-Drug Related Adverse Events
HCV Recurrence
After Transplantation
Hearing
Hematological
Growth Factors
Hemodialysis
Hemoglobin
Hemophilia
Hepatic Decompensation
Hepatic Failure
Hematological Disorders
Hepatocellular
Carcinoma
Histology
Hormone
Therapies
hyaluronate
(HA)
Immunoglobulins
Immunosuppression
Induction Therapy
Injection Drug
Use
Infergen
Insulin Resistance
Interferon
Interferon
Resistance
Intron A
Kidney Disorders
Kidney Transplant
Liver Biopsy
Liver Enzymes
Liver
Issues
Living Donors
Liver Stiffness Measurement
(LSM)
Maintenance Therapy
Methadone
Miscellaneous
Mortality and Morbidity
Monotherapy Treatment
Mother
to Child Transmission of HCV
Natural
History
Neutropenia
Non-Alcoholic
Fatty Liver
Disease (NAFLD)
Non-Hepatic
Cancers
Non-Hodgkins
Lymphoma
Non-organ
Specific Autoantibodies
Nonresponders
/ Relapsers
Obesity
Occult
HBV Infection
Pathogenesis
Pegasys
PEG-Intron
Pegylated
Inferferon
Pharmacokinetics
Platelets
Pregnancy
Productivity
PIIINP/MMP-1,
prothrombin time (PT)
Quality
of Life
Quasispecies
Rapid
Virologic Response (RVR)
Recurrent
HCV
Re-Treatment
Retinopathy
Ribavirin
Ribavirin
Dosing
Risk
Factors for HCC
Risk
Factors
Roferon
Seroconversion
Sex
(gender)
Sexual
Transmission
Skin
Reactions / Diseases
Sleeplessness
Steatosis
Steroids
Superinfection
Survival
Sustained Viral Response
Toxicities and Side Events
Transmission
Transplantation
Undetectable
HCV RNA
Viral
Eradication
Viral
Kinetics
Viral
Load
Weight-based
Dosing
Women
and Children
|
